Randomized trial promoting cancer genetic risk assessment when genetic counseling cost removed: 1-year follow-up.

Cancer Genetic Risk Assessment (CGRA) is recommended for women with ovarian and high-risk breast cancer. However, the underutilization of CGRA has long been documented, and cost has been a major barrier. In this randomized controlled trial, a Tailored Counseling and Navigation (TCN) intervention significantly improved CGRA uptake at 6-month follow-up, compared with Targeted Print (TP) and Usual Care (UC). We aimed to examine the effect of removing genetic counseling costs on CGRA uptake by 12 months. We recruited racially and geographically diverse women with breast and ovarian cancer from cancer registries in Colorado, New Jersey, and New Mexico. Participants assigned to TCN received phone-based psychoeducation and navigation. After 6 months, the trial provided free genetic counseling to participants in all arms. At 12 months, more women in TCN obtained CGRA (26.6%) than those in TP (11.0%, Odds ratio (OR) = 2.77, 95% Confidence interval (CI) 1.56 to 4.89) and UC (12.2%, OR = 2.46, 95% CI 1.41 to 4.29). There were no significant differences in CGRA uptake between TP and UC. The Kaplan-Meier curve shows that the divergence of cumulative incidence slopes (TCN vs UC, TCN vs TP) appears primarily within the initial 6 months. TCN significantly increased CGRA uptake at the 12-month follow-up. Directly removing the costs of genetic counseling attenuated the effects of TCN, highlighting the critical enabling role played by cost coverage. Future policies and interventions should address multi-level cost-related barriers to expand patients' access to CGRA. This trial was registered with the NIH clinical trial registry, clinicaltrials.gov, NCT03326713. https://clinicaltrials.gov/ct2/show/NCT03326713.

Informations de copyright

Published by Oxford University Press 2024.